ATE440949T1 - Gesteuertes überlesen von stopcodons - Google Patents

Gesteuertes überlesen von stopcodons

Info

Publication number
ATE440949T1
ATE440949T1 AT05700620T AT05700620T ATE440949T1 AT E440949 T1 ATE440949 T1 AT E440949T1 AT 05700620 T AT05700620 T AT 05700620T AT 05700620 T AT05700620 T AT 05700620T AT E440949 T1 ATE440949 T1 AT E440949T1
Authority
AT
Austria
Prior art keywords
polypeptide
interest
stop codon
cells expressing
cells
Prior art date
Application number
AT05700620T
Other languages
English (en)
Inventor
Thomas Bouquin
Original Assignee
Maxygen Holdings Ltd
Maxygen Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34830514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE440949(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Maxygen Holdings Ltd, Maxygen Aps filed Critical Maxygen Holdings Ltd
Application granted granted Critical
Publication of ATE440949T1 publication Critical patent/ATE440949T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT05700620T 2004-01-30 2005-01-28 Gesteuertes überlesen von stopcodons ATE440949T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54082004P 2004-01-30 2004-01-30
US63130604P 2004-11-29 2004-11-29
PCT/DK2005/000070 WO2005073375A1 (en) 2004-01-30 2005-01-28 Regulated stop codon readthrough

Publications (1)

Publication Number Publication Date
ATE440949T1 true ATE440949T1 (de) 2009-09-15

Family

ID=34830514

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05700620T ATE440949T1 (de) 2004-01-30 2005-01-28 Gesteuertes überlesen von stopcodons

Country Status (7)

Country Link
US (1) US20070224635A1 (de)
EP (1) EP1716233B1 (de)
AT (1) ATE440949T1 (de)
DE (1) DE602005016218D1 (de)
DK (1) DK1716233T3 (de)
ES (1) ES2329807T3 (de)
WO (1) WO2005073375A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825231B2 (en) * 2005-06-01 2010-11-02 Darren P. Wolfe Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
US20090304641A1 (en) * 2005-10-17 2009-12-10 Children's Hospital Boston Methods and Compositions for Regulating Gene Expression
KR101734585B1 (ko) * 2008-08-28 2017-05-11 노파르티스 아게 정지 코돈 번역초과에 의한 폴리펩티드 이소형의 세포 표면 표시
US20110165583A1 (en) * 2008-09-02 2011-07-07 Lupin Limited Vector for identification, selection and expression of recombinants
PT2401377T (pt) 2009-02-27 2016-08-18 Novartis Ag Sistema de vectores de expressão compreendendo dois marcadores de selecção
WO2011140529A1 (en) * 2010-05-07 2011-11-10 Lakepharma, Inc. Surface markers and uses thereof for rapid stable cell line generation and gene amplification
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
EP2834259A4 (de) 2012-04-02 2016-08-24 Moderna Therapeutics Inc Modifizierte polynukleotide
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US10054583B2 (en) * 2012-10-10 2018-08-21 Temple University Of The Commonwealth System Of Higher Education Nuclear factor-erythroid 2 related factor 2 (NRF2) biosensors and modulators of NRF2
WO2014066404A2 (en) * 2012-10-22 2014-05-01 Life Technologies Corporation System and method for visualization of optimized protein expression
SG11201503326PA (en) 2012-11-20 2015-06-29 Novartis Ag Optimized expression cassette for expressing a polypeptide with high yield
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
EP2925867B1 (de) * 2012-11-30 2018-06-27 Larix Biosciences LLC Neuartiges screening-verfahren für zelllinien
US20160017319A1 (en) 2013-03-11 2016-01-21 Audrey Nommay Method of screening cell clones
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20140323315A1 (en) 2013-04-29 2014-10-30 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
RU2716977C2 (ru) 2013-07-31 2020-03-17 Новартис Аг Новые селективные векторы и способы селекции эукариотических клеток-хозяев
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
AU2014369177B2 (en) 2013-12-20 2017-04-20 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
EP3604331A1 (de) 2013-12-20 2020-02-05 Novartis AG Neuartige eukaryotische zellen und verfahren zur rekombinanten expression eines produkts von interesse
TWI664190B (zh) * 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
KR20230154074A (ko) * 2021-03-08 2023-11-07 난징 진스크립트 바이오테크 컴퍼니 리미티드 이중 바이러스 벡터 시스템을 이용한 항체 전달
JP2024520790A (ja) * 2021-06-10 2024-05-24 ヤンセン バイオテツク，インコーポレーテツド Ｋｌｋ２－ｇｐｉ融合タンパク質をコードする核酸、組換え細胞、及びその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264341A (en) * 1989-08-30 1993-11-23 Eli Lilly And Company Selective cloning for high monoclonal antibody secreting hybridomas
EP0663953B1 (de) * 1992-09-04 2001-12-05 The Scripps Research Institute Phagemiden die einen oberflächenrezeptor und ein heterologes oberflächenprotein co-exprimieren
US20030124555A1 (en) * 2001-05-21 2003-07-03 Invitrogen Corporation Compositions and methods for use in isolation of nucleic acid molecules
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
US20020086427A1 (en) * 2000-03-23 2002-07-04 Leiden Jeffrey M. Inducible eukaryotic expression system that regulates protein translation
DE10053224A1 (de) * 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
JP2004538002A (ja) * 2001-08-02 2004-12-24 アルタナ　ファルマ　アクチエンゲゼルシャフト 停止コドン抑制による組み換え遺伝子発現の新規方法
PT1652920E (pt) * 2001-10-01 2010-11-08 Deutsches Krebsforsch Processo para a produção de bibliotecas de proteínas e para a selecção de proteínas a partir da mesma
US20040101823A1 (en) * 2001-12-21 2004-05-27 Maxygen, Inc. HIV-1 viral variants for improved animal models of HIV-1 pathogenesis
US7833741B2 (en) * 2002-08-07 2010-11-16 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
EP2395016A3 (de) * 2003-05-30 2012-12-19 Merus B.V. Entwurf und Verwendung von gepaarten unterschiedlichen Regionen von spezifisch bindenden Molekülen

Also Published As

Publication number Publication date
EP1716233A1 (de) 2006-11-02
ES2329807T3 (es) 2009-12-01
DK1716233T3 (da) 2009-10-26
WO2005073375A1 (en) 2005-08-11
US20070224635A1 (en) 2007-09-27
DE602005016218D1 (de) 2009-10-08
EP1716233B1 (de) 2009-08-26

Similar Documents

Publication Publication Date Title
ATE440949T1 (de) Gesteuertes überlesen von stopcodons
Baiocchini et al. Extracellular matrix molecular remodeling in human liver fibrosis evolution
Pethő et al. Mechanosensitive ion channels push cancer progression
Fröls Archaeal biofilms: widespread and complex
Bao et al. Plant roots use a patterning mechanism to position lateral root branches toward available water
Cohen-Salmon et al. Connexin30 deficiency causes instrastrial fluid–blood barrier disruption within the cochlear stria vascularis
WO2007047578A3 (en) Cell display of antibody libraries
WO2019210268A3 (en) Sequencing-based proteomics
MX2020009907A (es) Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular.
EP2348126A3 (de) Herstellung von Anti-Amyloid-Beta Antikörpern
WO2005072129A9 (en) Production of host cells containing mutiple integrating vectors by serial transduction
EA200600345A1 (ru) Способ культивирования клеток
CY1111769T1 (el) Παρασκευη κυτταρων
WO2008060483A3 (en) Protein-protein interaction biosensors and methods of use thereof
ES2153358T3 (es) Procedimientos para la seleccion de celulas huespedes recombinantes que expresan altos niveles de una proteina deseada.
Zhang et al. Calcified coccoid from Cambrian Miaolingian: Revealing the potential cellular structure of Epiphyton
WO2005065348A3 (en) Transactivation system for mammalian cells
Maróti et al. Discovery of [NiFe] hydrogenase genes in metagenomic DNA: cloning and heterologous expression in Thiocapsa roseopersicina
Piro et al. Leaf proteome modulation and cytological features of seagrass Cymodocea nodosa in response to long-term high CO2 exposure in volcanic vents
DK1812046T3 (da) Melanocortinreceptor-bindende mimetilegemer, sammensætninger, fremgangsmåder og anvendelser
WO2007051063A3 (en) Gpcr expressing cell lines and antibodies
ATE320485T1 (de) Mutierte furin polypeptide, welche verbesserte eigenschaften aufweisen
Huang The great American biotic interchange and diversification history in Dynastes beetles (Scarabaeidae; Dynastinae)
Jensen et al. Zinc fixation preserves flow cytometry scatter and fluorescence parameters and allows simultaneous analysis of DNA content and synthesis, and intracellular and surface epitopes
Wilke et al. Streamlining homogeneous glycoprotein production for biophysical and structural applications by targeted cell line development

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties